{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T21:22:58Z","timestamp":1785446578784,"version":"3.56.0"},"reference-count":46,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Nanomedicine: Nanotechnology, Biology and Medicine"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.nano.2024.102773","type":"journal-article","created":{"date-parts":[[2024,7,2]],"date-time":"2024-07-02T06:58:38Z","timestamp":1719903518000},"page":"102773","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Neuroprotective macromolecular methylprednisolone prodrug nanomedicine prevents glucocorticoid-induced muscle atrophy and osteoporosis in a rat model of spinal cord injury"],"prefix":"10.1016","volume":"62","author":[{"given":"Yiwen","family":"Qin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenshan","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William A.","family":"Bauman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanzhen","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"X. Edward","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zihao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiming","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher P.","family":"Cardozo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiping","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.nano.2024.102773_bb0005","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1602\/neurorx.1.1.80","article-title":"Neuroprotection and acute spinal cord injury: a reappraisal","volume":"1","author":"Hall","year":"2004","journal-title":"NeuroRx"},{"issue":"20","key":"10.1016\/j.nano.2024.102773_bb0010","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1056\/NEJM199005173222001","article-title":"A randomized, controlled trial of methylprednisolone or naloxone in the treatment of acute spinal-cord injury. Results of the second national acute spinal cord injury study","volume":"322","author":"Bracken","year":"1990","journal-title":"N Engl J Med"},{"issue":"20","key":"10.1016\/j.nano.2024.102773_bb0015","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1001\/jama.1997.03540440031029","volume":"277","author":"Bracken","year":"1997","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.nano.2024.102773_bb0020","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1089\/neur.2021.0035","article-title":"Administration of high-dose methylprednisolone worsens bone loss after acute spinal cord injury in rats","volume":"2","author":"Peng","year":"2021","journal-title":"Neurotrauma Rep"},{"key":"10.1016\/j.nano.2024.102773_bb0025","article-title":"Localized delivery of methylprednisolone sodium succinate with polymeric nanoparticles in experimental injured spinal cord model","volume":"1-10","author":"Karabey-Akyurek","year":"2016","journal-title":"Pharm Dev Technol"},{"issue":"5","key":"10.1016\/j.nano.2024.102773_bb0030","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1002\/smll.201201888","article-title":"Microglia response and in vivo therapeutic potential of methylprednisolone-loaded dendrimer nanoparticles in spinal cord injury","volume":"9","author":"Cerqueira","year":"2013","journal-title":"Small"},{"issue":"13","key":"10.1016\/j.nano.2024.102773_bb0035","doi-asserted-by":"crossref","first-page":"2582","DOI":"10.1016\/j.biomaterials.2008.12.077","article-title":"Nanoparticle-mediated local delivery of methylprednisolone after spinal cord injury","volume":"30","author":"Kim","year":"2009","journal-title":"Biomaterials"},{"issue":"1","key":"10.1016\/j.nano.2024.102773_bb0040","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s12951-019-0449-3","article-title":"NEP1-40-modified human serum albumin nanoparticles enhance the therapeutic effect of methylprednisolone against spinal cord injury","volume":"17","author":"Lin","year":"2019","journal-title":"J Nanobiotechnology"},{"issue":"12","key":"10.1016\/j.nano.2024.102773_bb0045","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1016\/j.biomaterials.2008.01.002","article-title":"Spatial distribution and acute anti-inflammatory effects of methylprednisolone after sustained local delivery to the contused spinal cord","volume":"29","author":"Chvatal","year":"2008","journal-title":"Biomaterials"},{"issue":"8","key":"10.1016\/j.nano.2024.102773_bb0050","doi-asserted-by":"crossref","first-page":"972","DOI":"10.3109\/10837450.2016.1143002","article-title":"Localized delivery of methylprednisolone sodium succinate with polymeric nanoparticles in experimental injured spinal cord model","volume":"22","author":"Karabey-Akyurek","year":"2017","journal-title":"Pharm Dev Technol"},{"issue":"59","key":"10.1016\/j.nano.2024.102773_bb0055","doi-asserted-by":"crossref","first-page":"99666","DOI":"10.18632\/oncotarget.20649","article-title":"Synthesis of methylprednisolone loaded ibuprofen modified dextran based nanoparticles and their application for drug delivery in acute spinal cord injury","volume":"8","author":"Qi","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.nano.2024.102773_bb0060","article-title":"Sampling blood from the lateral tail vein of the rat","volume":"99","author":"Lee","year":"2015","journal-title":"J Vis Exp"},{"issue":"9","key":"10.1016\/j.nano.2024.102773_bb0065","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1007\/s00198-014-2748-8","article-title":"Effects of low intensity vibration on bone and muscle in rats with spinal cord injury","volume":"25","author":"Bramlett","year":"2014","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.nano.2024.102773_bb0070","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1111\/j.1749-6632.2009.05313.x","article-title":"Nandrolone slows hindlimb bone loss in a rat model of bone loss due to denervation","volume":"1192","author":"Cardozo","year":"2010","journal-title":"Ann N Y Acad Sci"},{"issue":"11","key":"10.1016\/j.nano.2024.102773_bb0075","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1002\/jbmr.2549","article-title":"Sclerostin antibody preserves the morphology and structure of osteocytes and blocks the severe skeletal deterioration after motor-complete spinal cord injury in rats","volume":"30","author":"Qin","year":"2015","journal-title":"J Bone Miner Res"},{"issue":"4","key":"10.1016\/j.nano.2024.102773_bb0080","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/s00223-018-0439-8","article-title":"Sclerostin antibody reverses the severe sublesional bone loss in rats after chronic spinal cord injury","volume":"103","author":"Zhao","year":"2018","journal-title":"Calcif Tissue Int"},{"issue":"6","key":"10.1016\/j.nano.2024.102773_bb0085","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1179\/2045772312Y.0000000020","article-title":"Anabolic steroids reduce spinal cord injury-related bone loss in rats associated with increased Wnt signaling","volume":"36","author":"Sun","year":"2013","journal-title":"J Spinal Cord Med"},{"issue":"19","key":"10.1016\/j.nano.2024.102773_bb0090","doi-asserted-by":"crossref","first-page":"13511","DOI":"10.1074\/jbc.M113.454892","article-title":"The central nervous system (CNS)-independent anti-bone-resorptive activity of muscle contraction and the underlying molecular and cellular signatures","volume":"288","author":"Qin","year":"2013","journal-title":"J Biol Chem"},{"issue":"12","key":"10.1016\/j.nano.2024.102773_bb0095","doi-asserted-by":"crossref","first-page":"3627","DOI":"10.1007\/s00198-016-3700-x","article-title":"Mice with sclerostin gene deletion are resistant to the severe sublesional bone loss induced by spinal cord injury","volume":"27","author":"Qin","year":"2016","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.nano.2024.102773_bb0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.bone.2020.115825","article-title":"Electrical stimulation of hindlimb skeletal muscle has beneficial effects on sublesional bone in a rat model of spinal cord injury","volume":"144","author":"Zhao","year":"2021","journal-title":"Bone"},{"issue":"6","key":"10.1016\/j.nano.2024.102773_bb0105","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1016\/j.celrep.2018.01.041","article-title":"beta-aminoisobutyric acid, l-BAIBA, is a muscle-derived osteocyte survival factor","volume":"22","author":"Kitase","year":"2018","journal-title":"Cell Rep"},{"key":"10.1016\/j.nano.2024.102773_bb0110","author":"Lenth"},{"issue":"4","key":"10.1016\/j.nano.2024.102773_bb0115","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1023\/A:1027352703783","article-title":"Differential gene expression in the rat skeletal and heart muscle in glucocorticoid-induced myopathy: analysis by microarray","volume":"17","author":"Komamura","year":"2003","journal-title":"Cardiovasc Drugs Ther"},{"issue":"1","key":"10.1016\/j.nano.2024.102773_bb0120","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1096\/fj.03-0610com","article-title":"Multiple types of skeletal muscle atrophy involve a common program of changes in gene expression","volume":"18","author":"Lecker","year":"2004","journal-title":"FASEB J"},{"issue":"4","key":"10.1016\/j.nano.2024.102773_bb0125","doi-asserted-by":"crossref","first-page":"E785","DOI":"10.1152\/ajpendo.00646.2007","article-title":"The glucocorticoid receptor and FOXO1 synergistically activate the skeletal muscle atrophy-associated MuRF1 gene","volume":"295","author":"Waddell","year":"2008","journal-title":"Am J Physiol Endocrinol Metab"},{"issue":"3","key":"10.1016\/j.nano.2024.102773_bb0130","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/S0092-8674(04)00400-3","article-title":"Foxo transcription factors induce the atrophy-related ubiquitin ligase atrogin-1 and cause skeletal muscle atrophy","volume":"117","author":"Sandri","year":"2004","journal-title":"Cell"},{"issue":"2","key":"10.1016\/j.nano.2024.102773_bb0135","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1016\/j.bbrc.2014.06.080","article-title":"Identification of functional glucocorticoid response elements in the mouse FoxO1 promoter","volume":"450","author":"Qin","year":"2014","journal-title":"Biochem Biophys Res Commun"},{"issue":"1","key":"10.1016\/j.nano.2024.102773_bb0140","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1152\/japplphysiol.00704.2009","article-title":"Time course expression of Foxo transcription factors in skeletal muscle following corticosteroid administration","volume":"108","author":"Cho","year":"2010","journal-title":"J Appl Physiol (1985)"},{"issue":"1","key":"10.1016\/j.nano.2024.102773_bb0145","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1210\/en.2006-0539","article-title":"Myostatin gene deletion prevents glucocorticoid-induced muscle atrophy","volume":"148","author":"Gilson","year":"2007","journal-title":"Endocrinology"},{"issue":"7","key":"10.1016\/j.nano.2024.102773_bb0150","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/j.injury.2007.12.005","article-title":"Early complications of high-dose methylprednisolone in acute spinal cord injury patients","volume":"39","author":"Suberviola","year":"2008","journal-title":"Injury"},{"issue":"5","key":"10.1016\/j.nano.2024.102773_bb0155","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1152\/japplphysiol.00122.2013","article-title":"Skeletal muscle signaling associated with impaired glucose tolerance in spinal cord-injured men and the effects of contractile activity","volume":"115","author":"Yarar-Fisher","year":"2013","journal-title":"J Appl Physiol (1985)"},{"issue":"3 Pt 1","key":"10.1016\/j.nano.2024.102773_bb0160","first-page":"E593","article-title":"Intact glucose transport in morphologically altered denervated skeletal muscle from quadriplegic patients","volume":"271","author":"Aksnes","year":"1996","journal-title":"Am J Physiol"},{"issue":"4","key":"10.1016\/j.nano.2024.102773_bb0165","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1038\/sj.sc.3101681","article-title":"High-dose methylprednisolone may cause myopathy in acute spinal cord injury patients","volume":"43","author":"Qian","year":"2005","journal-title":"Spinal Cord"},{"issue":"8","key":"10.1016\/j.nano.2024.102773_bb0170","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1038\/sc.2011.28","article-title":"The administration of high-dose methylprednisolone for 24 h reduced muscle size and increased atrophy-related gene expression in spinal cord-injured rats","volume":"49","author":"Wu","year":"2011","journal-title":"Spinal Cord"},{"issue":"4","key":"10.1016\/j.nano.2024.102773_bb0175","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1038\/ki.2012.84","article-title":"Transcription factor FoxO1, the dominant mediator of muscle wasting in chronic kidney disease, is inhibited by microRNA-486","volume":"82","author":"Xu","year":"2012","journal-title":"Kidney Int"},{"key":"10.1016\/j.nano.2024.102773_bb0180","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1111\/j.1749-6632.2010.05806.x","article-title":"Bone and muscle loss after spinal cord injury: organ interactions","volume":"1211","author":"Qin","year":"2010","journal-title":"Ann N Y Acad Sci"},{"issue":"10","key":"10.1016\/j.nano.2024.102773_bb0185","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1007\/s00198-007-0394-0","article-title":"Glucocorticoid-induced osteoporosis: pathophysiology and therapy","volume":"18","author":"Canalis","year":"2007","journal-title":"Osteoporos Int"},{"issue":"2","key":"10.1016\/j.nano.2024.102773_bb0190","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1172\/JCI2799","article-title":"Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids. Potential mechanisms of their deleterious effects on bone","volume":"102","author":"Weinstein","year":"1998","journal-title":"J Clin Invest"},{"issue":"10","key":"10.1016\/j.nano.2024.102773_bb0195","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1007\/s001980200108","article-title":"The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis","volume":"13","author":"van Staa","year":"2002","journal-title":"Osteoporos Int"},{"issue":"2","key":"10.1016\/j.nano.2024.102773_bb0200","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.pmrj.2014.08.948","article-title":"Osteoporosis in individuals with spinal cord injury","volume":"7","author":"Bauman","year":"2015","journal-title":"PM R"},{"issue":"3","key":"10.1016\/j.nano.2024.102773_bb0205","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1682\/JRRD.2004.05.0062","article-title":"Effect of pamidronate administration on bone in patients with acute spinal cord injury","volume":"42","author":"Bauman","year":"2005","journal-title":"J Rehabil Res Dev"},{"issue":"8914","key":"10.1016\/j.nano.2024.102773_bb0210","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S0140-6736(94)91049-9","article-title":"Generalised bone loss in patients with early rheumatoid arthritis","volume":"344","author":"Gough","year":"1994","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.nano.2024.102773_bb0215","doi-asserted-by":"crossref","first-page":"4382","DOI":"10.1210\/endo.140.10.7034","article-title":"Stimulation of osteoprotegerin ligand and inhibition of osteoprotegerin production by glucocorticoids in human osteoblastic lineage cells: potential paracrine mechanisms of glucocorticoid-induced osteoporosis","volume":"140","author":"Hofbauer","year":"1999","journal-title":"Endocrinology"},{"issue":"11","key":"10.1016\/j.nano.2024.102773_bb0220","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1136\/ard.45.11.950","article-title":"Osteoporosis in rheumatoid arthritis: safety of low dose corticosteroids","volume":"45","author":"Sambrook","year":"1986","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"10.1016\/j.nano.2024.102773_bb0225","first-page":"1495","article-title":"Limited bone loss due to corticosteroids; a systematic review of prospective studies in rheumatoid arthritis and other diseases","volume":"24","author":"Verhoeven","year":"1997","journal-title":"J Rheumatol"},{"issue":"10","key":"10.1016\/j.nano.2024.102773_bb0230","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1136\/ard.45.10.852","article-title":"Vertebral and peripheral bone mineral content and fracture incidence in postmenopausal patients with rheumatoid arthritis: effect of low dose corticosteroids","volume":"45","author":"Verstraeten","year":"1986","journal-title":"Ann Rheum Dis"}],"container-title":["Nanomedicine: Nanotechnology, Biology and Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S154996342400042X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S154996342400042X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,24]],"date-time":"2024-10-24T07:26:07Z","timestamp":1729754767000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S154996342400042X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":46,"alternative-id":["S154996342400042X"],"URL":"https:\/\/doi.org\/10.1016\/j.nano.2024.102773","relation":{},"ISSN":["1549-9634"],"issn-type":[{"value":"1549-9634","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Neuroprotective macromolecular methylprednisolone prodrug nanomedicine prevents glucocorticoid-induced muscle atrophy and osteoporosis in a rat model of spinal cord injury","name":"articletitle","label":"Article Title"},{"value":"Nanomedicine: Nanotechnology, Biology and Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nano.2024.102773","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"102773"}}